{"id":753,"date":"2026-09-01T16:45:45","date_gmt":"2026-09-01T16:45:45","guid":{"rendered":"https:\/\/nhdbio.com\/resources\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/"},"modified":"2026-09-01T16:45:45","modified_gmt":"2026-09-01T16:45:45","slug":"thymosin-alpha-1-tests-phase-3-sepsis-trial-2025","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/fr\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/","title":{"rendered":"Thymosin Alpha-1 dans le sepsis\u00a0: le r\u00e9sultat 2025 TESTS de la phase 3"},"content":{"rendered":"
L'essai 2025 TESTS est plus informatif que les rapports ant\u00e9rieurs sur les petits sepsis\u00a0: les adultes 1,106 ont \u00e9t\u00e9 randomis\u00e9s dans les centres 22, et la thymosine alpha-1 n'a pas r\u00e9duit la mortalit\u00e9 toutes causes confondues par jour 28.<\/p>
Les preuves en un coup d'\u0153il<\/h2>
L'essai a randomis\u00e9 des adultes 1,106\u00a0; Les 1,089 ont \u00e9t\u00e9 inclus dans l\u2019analyse modifi\u00e9e en intention de traiter.<\/li>
La mortalit\u00e9 \u00e0 28 jours \u00e9tait de 23.4% avec la thymosine alpha-1 et de 24.1% avec le placebo.<\/li>
Le rapport de risque \u00e9tait 0.99 (95% CI 0.77 \u2013 1.27\u00a0; P = 0.93) et aucun r\u00e9sultat secondaire ou de s\u00e9curit\u00e9 ne diff\u00e9rait de mani\u00e8re significative.<\/li><\/ul><\/div><\/div>Illustration originale de recherche \u00e9ditoriale. Il ne s\u2019agit pas d\u2019une figure d\u2019\u00e9tude, d\u2019une image d\u2019un patient, d\u2019une photographie de produit, d\u2019un r\u00e9sultat d\u2019analyse fourni ou d\u2019une repr\u00e9sentation d\u2019un lot du catalogue.<\/figcaption><\/figure>
Dossier d'\u00e9tudes<\/h2>
Le crit\u00e8re d'\u00e9valuation principal \u00e9tait le d\u00e9c\u00e8s, quelle qu'en soit la cause, dans les jours 28. Le rapport de risque proche de l\u2019unit\u00e9 et l\u2019intervalle de confiance franchissant celui-ci ne fournissent aucune preuve claire d\u2019une r\u00e9duction de la mortalit\u00e9 dans la population globale de l\u2019essai.<\/p>
Conception<\/strong>Phase multicentrique, en double aveugle, randomis\u00e9e et contr\u00f4l\u00e9e par placebo 3<\/span><\/div>
Sites<\/strong>Centres 22 en Chine<\/span><\/div>
ITT modifi\u00e9<\/strong>542 thymosine alpha-1; Placebo 547<\/span><\/div>
Mortalit\u00e9 par jour 28<\/strong>23.4% contre 24.1%<\/span><\/div>
Estimation de l'effet<\/strong>HR 0.99; 95% CI 0.77\u20131.27\u00a0; P=0.93<\/span><\/div><\/div><\/div>
R\u00e9sultats en contexte<\/h2>
Les interactions de sous-groupes pr\u00e9d\u00e9finis en fonction de l'\u00e2ge et du diab\u00e8te ont g\u00e9n\u00e9r\u00e9 d'\u00e9ventuels signaux diff\u00e9rentiels. Les sous-groupes sont utiles pour concevoir des \u00e9tudes futures, mais ils n\u2019inversent pas un r\u00e9sultat primaire neutre et ne doivent pas \u00eatre annonc\u00e9s comme des indications \u00e9tablies.<\/p>
Une m\u00e9ta-analyse 2025 a regroup\u00e9 les essais randomis\u00e9s 11 avec des participants 1,927 et a trouv\u00e9 un rapport de cotes global de 0.73. Pourtant, ses sous-ensembles multicentriques de haute qualit\u00e9 n\u2019\u00e9taient pas statistiquement significatifs, et l\u2019analyse s\u00e9quentielle des essais a jug\u00e9 l\u2019\u00e9chantillon disponible inad\u00e9quat. Le grand r\u00e9sultat TESTS appartient donc au centre de tout r\u00e9sum\u00e9 actuel.<\/p>
Ce que la preuve ne peut \u00e9tablir<\/h2>
Un essai national peut ne pas repr\u00e9senter tous les syst\u00e8mes de sant\u00e9 ou ph\u00e9notypes de sepsis.<\/p>
Les effets des sous-groupes doivent \u00eatre confirm\u00e9s et doivent rester g\u00e9n\u00e9rateurs d\u2019hypoth\u00e8ses.<\/p>
Un essai clinique d\u2019une intervention termin\u00e9e ne valide pas un lot de recherche sans rapport.<\/p>","protected":false},"excerpt":{"rendered":"
L'essai 2025 TESTS est plus informatif que les rapports ant\u00e9rieurs sur les petits sepsis\u00a0: les adultes 1,106 ont \u00e9t\u00e9 randomis\u00e9s dans les centres 22, et la thymosine alpha-1 n'a pas r\u00e9duit la mortalit\u00e9 toutes causes confondues par jour 28.<\/p>","protected":false},"author":1,"featured_media":737,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"369","pim_article_type":"Published evidence review","pim_evidence_level":"Large multicenter randomized phase 3 human trial with a neutral primary outcome","pim_reviewer":"Site evidence editorial team","pim_reviewed_date":"2026-09-02","pim_editorial_note":"Source-checked on 2026-09-02. Null results, study size, model\/population limits and relevant conflicts are retained. This is not medical advice, a customer case or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"Primary\/regulatory sources, factual claims, numerical results, limitations and product-evidence boundary checked for batch 3.","pim_creation_method":"The editorial workflow began with linked PubMed primary papers, systematic reviews, PubChem identity records and FDA\/DailyMed regulatory records. Population or model, denominators, endpoints, numerical results, null findings, limitations and conflicts were extracted before drafting. AI-assisted drafting and original image generation were used; the final facts and evidence boundaries were checked against the linked records on 2026-09-02. This is not independent peer review.","pim_sources":"[{\"title\":\"TESTS phase 3 thymosin alpha-1 sepsis trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39814420\/\",\"note\":\"Primary 2025 multicenter trial; PMID 39814420.\"},{\"title\":\"2025 thymosin alpha-1 sepsis meta-analysis\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40969554\/\",\"note\":\"Eleven RCTs with quality and trial-sequential analyses; PMID 40969554.\"},{\"title\":\"PubChem Thymalfasin record\",\"url\":\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Thymalfasin\",\"note\":\"Sequence, formula, mass and synonym record; CID 16130571.\"}]","footnotes":""},"categories":[19],"tags":[],"class_list":["post-753","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-published-study-cases"],"yoast_head":"\n
Thymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result<\/title>\n<meta name=\"description\" content=\"The 2025 TESTS trial is more informative than earlier small sepsis reports: 1,106 adults were randomized across 22 centers, and thymosin alpha-1 did not re\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/fr\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Thymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result\" \/>\n<meta property=\"og:description\" content=\"The 2025 TESTS trial is more informative than earlier small sepsis reports: 1,106 adults were randomized across 22 centers, and thymosin alpha-1 did not re\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/fr\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T16:45:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Thymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result\",\"datePublished\":\"2026-09-01T16:45:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/\"},\"wordCount\":272,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/thymosin-alpha1-sepsis-evidence.webp\",\"articleSection\":[\"Published Study Reviews\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/\",\"name\":\"Thymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/thymosin-alpha1-sepsis-evidence.webp\",\"datePublished\":\"2026-09-01T16:45:45+00:00\",\"description\":\"The 2025 TESTS trial is more informative than earlier small sepsis reports: 1,106 adults were randomized across 22 centers, and thymosin alpha-1 did not re\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/thymosin-alpha1-sepsis-evidence.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/thymosin-alpha1-sepsis-evidence.webp\",\"width\":1672,\"height\":941,\"caption\":\"AI-generated illustration: Multicenter two-arm sepsis trial data visualization with near-overlapping outcomes\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Thymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/fr\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Thymosin Alpha-1 dans le sepsis\u00a0: le r\u00e9sultat 2025 TESTS de la phase 3","description":"L'essai 2025 TESTS est plus informatif que les rapports pr\u00e9c\u00e9dents sur les petits sepsis\u00a0: les adultes 1,106 ont \u00e9t\u00e9 randomis\u00e9s dans les centres 22, et la thymosine alpha-1 n'a pas r\u00e9\u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/fr\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/","og_locale":"fr_FR","og_type":"article","og_title":"Thymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result","og_description":"The 2025 TESTS trial is more informative than earlier small sepsis reports: 1,106 adults were randomized across 22 centers, and thymosin alpha-1 did not re\u2026","og_url":"https:\/\/nhdbio.com\/fr\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/","og_site_name":"NHD","article_published_time":"2026-09-01T16:45:45+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u00c9crit par":"NHD Technical Team","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Thymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result","datePublished":"2026-09-01T16:45:45+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/"},"wordCount":272,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence.webp","articleSection":["Published Study Reviews"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/","url":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/","name":"Thymosin Alpha-1 dans le sepsis\u00a0: le r\u00e9sultat 2025 TESTS de la phase 3","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence.webp","datePublished":"2026-09-01T16:45:45+00:00","description":"L'essai 2025 TESTS est plus informatif que les rapports pr\u00e9c\u00e9dents sur les petits sepsis\u00a0: les adultes 1,106 ont \u00e9t\u00e9 randomis\u00e9s dans les centres 22, et la thymosine alpha-1 n'a pas r\u00e9\u2026","breadcrumb":{"@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence.webp","width":1672,"height":941,"caption":"AI-generated illustration: Multicenter two-arm sepsis trial data visualization with near-overlapping outcomes"},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Thymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mati\u00e8res premi\u00e8res peptidiques et synth\u00e8se sur mesure","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"\u00c9quipe technique NHD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"L'\u00e9quipe technique NHD maintient la documentation du catalogue d'utilisation de la recherche et les r\u00e9sum\u00e9s des preuves. Les articles examin\u00e9s renvoient \u00e0 des articles \u00e9valu\u00e9s par des pairs, \u00e0 des registres d'essais et \u00e0 des dossiers r\u00e9glementaires, conservent les r\u00e9sultats nuls et les limites des \u00e9tudes, et distinguent les interventions publi\u00e9es des documents du catalogue. Le dessin assist\u00e9 par AI peut \u00eatre utilis\u00e9 pour la structure\u00a0; les liens vers les sources et les limites des preuves restent visibles. Ce travail ne constitue pas un examen ind\u00e9pendant par des pairs ni un avis m\u00e9dical.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/fr\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/753","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/comments?post=753"}],"version-history":[{"count":0,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/753\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media\/737"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media?parent=753"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/categories?post=753"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/tags?post=753"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Visualisation](\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence.webp\")